rss
J Clin Pathol doi:10.1136/jcp.2007.049585

Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma

  1. Joanna Yeung
  1. University Health Network, Toronto, Canada
    1. Hong Chang (hong.chang{at}uhn.on.ca)
    1. University Health Network/University of Toronto, Canada
      • Published Online First 12 December 2007

      Abstract

      As patients with multiple myeloma (MM) have a variable clinical course, predictive markers would help determine the appropriate treatment strategy. Clinical staging is commonly used to predict outcome but, tumor marker expression and the underlying genetic changes are increasingly used to assess the biological aggressiveness of the disease. Recent studies have demonstrated the utility of immunohistochemistry (IHC) in detecting prognostic markers including: fibroblast growth factor receptor 3, cyclin D1, c-maf and p53, which have been associated with various genetic aberrations including t(4;14), t(11;14), t(14;16), and del 17p. While t(4;14), t(14;16), and del (17p) have been documented to confer a poor prognosis, t(11;14) appears neutral or even favorable factor in some studies. CD56, CD33, CD20 and CXCR4 are promising surface marker due to their roles in MM progression but further studies of larger cohorts are necessary to assess their prognostic relevance. In this review, we discuss the biological function and clinical relevance of the main prognostic markers in MM and discuss the role of IHC in the stratification of patients into appropriate risk categories.

      This Article

      1. Abstract
      2. PDF
      3. All versions of this article:
        1. jcp.2007.049585v1
        2. jcp.2007.049585v2
        3. 61/7/832most recent

      Responses

      1. Submit a response
      2. No responses published

      Register for free content


      Free trial
      Individuals may register for a free 60 day online trial to all content.

      Free archive
      The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

      Don't forget to sign up for content alerts so you keep up to date with all the articles as they ar